ResearchDx Completes Service Offerings by Partnering with CompanDX

ResearchDx (Irvine, CA, USA) is partnering with CompanDX (Nottingham, United Kingdom) to discover and deliver novel molecular diagnostic tests for clients in the healthcare setting.

CompanDX uses its Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality, which are commonplace in clinical development of therapeutics. ResearchDx designs, produces and validates tests ready for the market and offers turnkey solutions for companion diagnostic delivery.

The new partnership will enable clients to initiate the development of companion diagnostic tests from the earliest stages of drug development. CompanDX has developed a set of tools to deliver an understanding of the mechanism of action and biomarkers that describe patient response.

ResearchDx is a Contract Diagnostics Organization (CDO) for the diagnostic and biopharmaceutic industries. The company's primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting. ResearchDx offers CLIA certified, CAP accredited high-complexity testing through its subsidiary, Pacific Diagnostics. It provides a full complement of cytogenetics, Fluorescence in situ hybridization (FISH), molecular and specialty services.

"Our partnership with CompanDX completes our service offerings," said founders of ResearchDx Dr. Philip Cotter and Dr. Mathew Moore. "CompanDX's unique capabilities allow us to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process. Our customers can trust ResearchDx to meet scientific challenges with a focus on their business priorities."

Related Links:
ResearchDx
CompanDX